Tag: GlobeNewswire

Preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropathy selected for oral presentation

Presentations on CLYM116 and budoprutug programs highlight advancements across the portfolio

WELLESLEY HILLS, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) — Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it will present new clinical data for its CLYM116 and budoprutug programs across three immune-mediated kidney diseases at the American Society of Nephrology (ASN) Kidney Week 2026, which will be held in Denver, Colorado from October 21-25, 2026.

Abstracts are available on the ASN 2026 website here.

Posters and Presentations

CLYM116

Title: CLYM116, a Novel “Sweeper” Anti-A PRoliferation-Inducing Ligand Monoclonal Antibody in Development for IgAN: Phase 1 Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) Results in Healthy Volunteers
Session Title: Pharmacology (PharmacoKinetics, -Dynamics, -Genomics) [PO1900]
Poster Number: TH-PO0823
Date / Time: October 22, 2026, from 10:00 AM to 12:00 p.m. MT

Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MIL116, a Novel “Sweeper” Anti-A PRoliferation-Inducing Ligand Monoclonal Antibody in Healthy Volunteers: Preliminary Phase 1 Results
Session Title: Glomerular Diseases: Practice and New Concepts Shaping Modern Care [PO1402-06]
Poster Number: FR-PO0838
Date / Time: October 23, 2026, from 10:00 AM to 12:00 p.m. MT

Budoprutug

Title: Preliminary Data from PrisMN, a Phase 2 Study Evaluating the Safety and Efficacy of Budoprutug, an Investigational Low-Fucosylated Anti-CD19 Monoclonal Antibody (mAb), in Patients with Primary Membranous Nephropathy (PMN)
Session Title: Glomerular Diseases: Clinical Trial Results [OR1402-3]
Session Room: Mile High Ballroom 4A (Convention Center)
Date / Time: October 24, 2026, from 5:30 PM to 5:40 p.m. MT

Title: Budoprutug for Minimal Change Disease (MCD): A Case Study of Durable Response and Potential Disease Modification via CD19+ B-Cell Depletion
Session Title: Glomerular Diseases: Membranous Nephropathy, FSGS, and Podocytopathies [PO1402-04]
Poster Number: FR-PO0713
Date / Time: October 23, 2026, from 10:00 AM to 12:00 p.m. MT

About Climb Bio, Inc.
Climb Bio, Inc. is a clinical-stage biotechnology company with a mission to deliver high impact, disease-modifying medicines for individuals living with immune-mediated diseases, including those affecting kidney health. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody being developed for IgA nephropathy. For more information, please visit climbbio.com.

About CLYM116
CLYM116 is a clinical-stage monoclonal antibody targeting APRIL (A Proliferation-Inducing Ligand), a key driver of pathogenic B-cell activity in autoimmune diseases. CLYM116 employs a novel pH-dependent bind-and-release ‘sweeper’ mechanism to potently block APRIL signaling, promote lysosomal degradation of APRIL, and recycle the antibody to extend its half-life. This differentiated design offers the potential for rapid, deep, and durable inhibition of APRIL with a favorable safety profile and less frequent dosing. CLYM116 is being advanced for the treatment of IgA nephropathy (IgAN) and may also have broader utility across other B-cell mediated diseases where APRIL plays a critical role.

About Budoprutug
Budoprutug is a clinical-stage, anti-CD19 monoclonal antibody with the potential to address a broad range of B-cell mediated, immune-driven diseases. Designed with enhanced effector function and low picomolar affinity, budoprutug targets and depletes CD19-expressing B cells, including plasmablasts and certain plasma cells, key sources of pathogenic autoantibodies. Early clinical data suggest budoprutug may offer durable B-cell depletion, rapid reductions in autoantibodies, and clinical remission in primary membranous nephropathy (pMN). Budoprutug is being evaluated in clinical trials for pMN, immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). A subcutaneous formulation is also in development to enable broader patient access. Budoprutug has been granted Orphan Drug Designation and Fast Track Designation by the FDA for the treatment of pMN.

Forward-Looking Statements
This press release contains “forward-looking statements” including without limitation statements regarding: expectations regarding the therapeutic benefits, clinical potential and clinical development of CLYM116 and budoprutug; the anticipated timelines for announcing data from Climb Bio’s ongoing and planned clinical trials; and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “expect,” “may,” “plan,” “potential,” “suggest,” “target,” “will” and similar expressions. Forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. Climb Bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, important risks and uncertainties associated with: the ability of Climb Bio to timely and successfully achieve or recognize the anticipated benefits of its acquisition of Tenet Medicines, Inc. and its technology transfer and exclusive license agreement with Mabworks; Climb Bio’s ability to advance budoprutug and CLYM116 on the timelines expected or at all and to obtain and maintain necessary approvals from the U.S. Food and Drug Administration and other regulatory authorities; obtaining and maintaining the necessary approvals from investigational review boards at clinical trial sites and independent data safety monitoring boards; replicating in clinical trials positive results found in early-stage clinical trials or nonclinical studies; competing successfully with other companies that are seeking to develop treatments for primary membranous nephropathy, immune thrombocytopenia, systemic lupus erythematosus, IgA nephropathy and other immune-mediated diseases; maintaining or protecting intellectual property rights related to budoprutug, CLYM116 and/or its other product candidates; managing expenses; changes in applicable laws or regulation; the possibility that Climb Bio may be adversely affected by other economic, business and/or competitive factors; and raising the substantial additional capital needed, on the timeline necessary, to continue development of budoprutug, CLYM116 and any other product candidates Climb Bio may develop. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Climb Bio’s actual results to differ materially from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in Climb Bio’s most recent filings with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Climb Bio’s views as of the date hereof and should not be relied upon as representing Climb Bio’s views as of any date subsequent to the date hereof. Climb Bio anticipates that subsequent events and developments will cause Climb Bio’s views to change. However, while Climb Bio may elect to update these forward-looking statements at some point in the future, Climb Bio specifically disclaims any obligation to do so, except as required by law.

Investors and Media
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com

AS LHV Group announces that during the period 25 September to 1 October 2026, it has acquired the company’s own shares on the Nasdaq Tallinn Stock Exchange as follows: 

Date	Aggregated volume (pcs)	Weighted average price per day (EUR)
25.09.2026	13,400	3.29
28.09.2026	26,800	3.2875
29.09.2026	18,033	3.283659957
30.09.2026	26,400	3.2725
01.10.2026	26,800	3.2675

 
LHV Group is acquiring its own shares based on the resolution of the company’s general meeting of shareholders held on 26 March 2025, and under the conditions decided by the Supervisory Board. The authorized agent for the transactions is AS LHV Pank. Summary data of the acquisitions will be disclosed no later than on the seventh trading day after the transaction and will be made available to the Financial Supervision and Resolution Authority, via the Nasdaq Tallinn system, and on LHV Group’s investor website. 

LHV Group is the largest domestic financial group and capital provider in Estonia. LHV Group’s main subsidiaries are LHV Pank, LHV Varahaldus, LHV Kindlustus and LHV Bank Limited. The Group employs nearly 1,200 people. LHV’s banking services are used by more than 514,000 customers, LHV-managed II pillar pension funds have 105,000 active customers and LHV Kindlustus provides insurance protection to 244,000 customers. LHV Bank, a subsidiary of LHV Group, holds a UK banking licence and offers banking services to international financial technology companies, loans to small and medium-sized enterprises and retail banking services.

 
Investor Relations 
Sten Hans Jakobsoo 
Head of Investor Relations and Corporate Development 
Email: stenhans.jakobsoo@lhv.ee 

Communications 
Paul Pihlak 
Head of Communications 
Email: paul.pihlak@lhv.ee  

Key Highlights

• Leveraged Bitcoin Treasury: Matador holds approximately 168 Bitcoin and funds its treasury through a combination of common equity and secured convertible debt.
• Convertible Note Facility: Matador has issued US$10.5 million principal amount of senior secured convertible notes under its US$100 million secured convertible note facility. The remaining US$89.5 million may be drawn in follow on closings, subject to regulatory approvals and other conditions.
• Capital Markets Tools: Since November 2025, the Company has put in place a C$80 million base shelf prospectus and, qualified under that shelf, a C$30 million at the market equity program, and amended its secured convertible note facility to expand at the market capacity. Shareholders will be asked to approve a new class of preferred shares on October 14, 2026.
• Cost Optimization: Management estimates that the Company’s cash operating expenditures currently average approximately C$125,000 per month, although monthly amounts vary, and that it continues to work toward a target of approximately C$100,000 per month, compared with average monthly net cash used in operating activities of approximately C$445,000 in the fiscal year ended October 31, 2025.
• Leadership: Donato Sferra was appointed Chief Executive Officer and Deven Soni was appointed Executive Chairman, each effective July 16, 2026.

TORONTO, Oct. 02, 2026 (GLOBE NEWSWIRE) — Matador Technologies Inc. (“Matador” or the “Company”) (TSXV:MATA)(OTCQB:MATAF)(FSE:IU3), the Bitcoin Ecosystem Company, today provided a corporate update summarizing developments in its capital structure, operations and governance since the beginning of its 2026 fiscal year on November 1, 2025.

During that period, the Company issued US$10.5 million principal amount of senior secured convertible notes under a US$100 million facility and used the proceeds to acquire 92 Bitcoin, established a C$80 million base shelf prospectus and a C$30 million at the market equity program qualified under that shelf, and reduced its cash operating expenditures to a current estimated average of approximately C$125,000 per month, with a target of approximately C$100,000 per month. Matador holds approximately 168 Bitcoin as its primary treasury asset. All dollar figures in this news release are stated in Canadian dollars unless otherwise indicated.

Bitcoin Treasury and Capital Structure

As at the date of this news release, Matador holds approximately 168 Bitcoin as its primary treasury asset, with approximately 138 Bitcoin held as collateral under the Company’s US$100 million secured convertible note facility (the “Facility”) and the senior secured convertible notes issued under it (the “Notes”).

Matador is structured as a leveraged Bitcoin treasury company that funds its Bitcoin holdings through a combination of common equity and secured convertible debt. Because a portion of the Company’s Bitcoin was acquired with borrowed capital, a change in the price of Bitcoin can have a proportionally larger effect on the Company’s net asset value attributable to common shareholders than on the value of the Bitcoin itself. This effect operates in both directions and can magnify losses as well as gains. The actual effect in any period will depend on factors including the Company’s operating costs, the cost of its debt and any issuances of common shares. The market price of the Company’s common shares may not reflect its net asset value at any given time.

Capital Markets Framework

The Company has assembled a set of capital markets tools intended to allow it to raise capital efficiently and to acquire additional Bitcoin when management considers that market conditions and its cost of capital make doing so accretive to Bitcoin held per share, while retaining the flexibility not to issue securities when they do not.

On December 22, 2025, the Ontario Securities Commission issued a final receipt for the Company’s C$80 million short form base shelf prospectus, which is effective for 25 months from that date. On February 3, 2026, the Company established an at the market equity program (the “ATM Program”) pursuant to an equity distribution agreement with ATB Cormark Capital Markets, permitting the Company to offer and sell common shares for aggregate gross proceeds of up to C$30 million at prevailing market prices on the TSX Venture Exchange (the “Exchange”). From the commencement of the ATM Program on February 4, 2026 to October 1, 2026:

• Common shares issued: 49,054,400
• Weighted average price per share: $0.0478
• Aggregate gross proceeds: $2,343,564.35
• Net proceeds: $2,233,171.24

Net proceeds from the ATM Program have been used for the purchase of Bitcoin, in support of the Company’s Bitcoin yield generation strategy, and for general working capital purposes.

The Facility has been amended twice during the period. A waiver and amendment agreement dated February 3, 2026 permitted the ATM Program under the terms of the Facility. Amendment No. 2, announced on August 17, 2026, introduced an alternative definition of a permitted at the market offering which, prior to any listing on a US senior exchange, removes the aggregate proceeds cap, pricing floor and daily volume limitations that previously applied to at the market issuances conducted under the Company’s Canadian shelf prospectus documents. In exchange, an amount equal to 10 percent of the net proceeds of each qualifying sale is applied to the purchase of Bitcoin, which is deposited as additional collateral under the Facility.

Proposed Preferred Share Class

As announced by the Company on August 28, 2026, the Exchange conditionally accepted, on August 25, 2026, a proposed amendment to the Company’s articles to create a new class of an unlimited number of preferred shares (the “Preferred Shares”). The amendment is presented to shareholders as Resolution #5 in the Company’s management information circular, and shareholder approval will be requested at the annual general and special meeting of shareholders to be held on October 14, 2026. The amendment remains subject to that approval and to final acceptance by the Exchange.

The Company has no current plans to issue Preferred Shares. Certain larger Bitcoin treasury companies, including Strategy Inc. (NASDAQ: MSTR), have used preferred equity as part of their capital structures, and the Company considers it prudent to have that option available. Because an amendment to the Company’s articles requires shareholder approval, which is ordinarily sought at the Company’s annual meeting, the Company will request that approval at the October 14, 2026 meeting so that the board of directors will have the flexibility to consider preferred equity in the future, should circumstances warrant, without waiting for a subsequent annual meeting. Any future issuance of Preferred Shares would require the approval of the board of directors and specific approval of the Exchange.

Cost Optimization and Operating Efficiency

Since the beginning of fiscal 2026, the Company has reviewed its operating cost structure and implemented several measures to reduce costs and improve efficiency. The Company has restructured its executive and consulting agreements and terminated certain consulting engagements that were no longer considered necessary. The Company has also adopted artificial intelligence based tools internally to automate certain tasks and to perform work that was previously carried out by external advisors, allowing more of its finance, reporting and administrative functions to be completed internally on a more efficient basis.

As a result of these measures, management estimates that the Company’s cash operating expenditures currently average approximately C$125,000 per month. This figure is an unaudited management estimate, is not a measure recognized under IFRS, and may vary from month to month, including as a result of non-recurring professional fees and costs associated with the Company’s financing activities. By comparison, net cash used in operating activities for the fiscal year ended October 31, 2025, as reported in the Company’s audited annual financial statements, was C$5,337,072, or an average of approximately C$445,000 per month. Expenditures in that period reflected the cost of establishing Matador as a public issuer and building the capital markets framework now available to it, including the reverse takeover completed on December 9, 2024, the Company’s change of business to a hybrid issuer and the professional work required to put its shelf prospectus and equity distribution arrangements in place. The Company continues to review its cost structure on a continuous basis and to look for further opportunities to operate more leanly, with the objective of reducing average monthly cash operating expenditures to approximately C$100,000. Management intends to continue optimizing the Company’s cost base beyond the reductions achieved to date, although there can be no assurance as to the amount or timing of any further reductions. Management’s objective is a lean, low cost treasury company with a durable long term business model that is better positioned to maintain its Bitcoin position through periods of price volatility.

Bitcoin Yield Generation and GODL, a Gold Asset Treasury Company

Matador conducts a Bitcoin yield generation strategy in collaboration with Galaxy Digital Holdings Ltd. (“Galaxy”) pursuant to an ISDA Agreement, principally through the systematic execution of covered calls, alongside other supplementary options and yield generation strategies facilitated by Galaxy. Premium income from the strategy is not dependent on an increase in the price of Bitcoin, although Bitcoin allocated to the strategy remains exposed to price movements and may be called away at strike prices below prevailing market prices. Premium income varies with market conditions, and there can be no assurance as to the amount of premium income in any future period.

GODL is being organized as a pure-play gold treasury company. GODL intends to acquire physical gold and gold-backed tokens and to measure its progress principally by reference to gold ounces per share (“GOPS”), being gold ounces held divided by fully diluted shares outstanding. GODL also intends to pursue a gold yield strategy, principally through specialist gold leasing, the writing of covered calls and, as that market develops, the lending of tokenized gold, with the objective of generating a positive net yield after costs that would be reinvested in additional gold in order to increase GOPS over time. There can be no assurance that GODL will generate a positive net yield in any period.

Matador has developed technology for the tokenization of gold and intends to monetize that technology by licensing it to GODL. Matador and GODL have negotiated a form of licence agreement (the “Licence”) under which GODL would be permitted to use Matador’s gold tokenization intellectual property to create, issue and manage tokenized gold products. The Licence has not been executed and its terms remain subject to change.

Under the arrangement as currently contemplated, Matador would receive a combination of cash consideration and common shares of GODL in connection with the closing of GODL’s first financing. Any shares received would be held by Matador and reflected in its net asset value, subject to the valuation and liquidity limitations that apply to a holding in a private company. The final terms, including the amount and form of consideration payable to Matador, may differ from those currently contemplated. The Licence and the transactions contemplated by it remain subject to Exchange approval and other regulatory requirements, and there can be no assurance that they will be completed or as to the value of any consideration Matador may receive.

The corporate structure by which GODL is established and taken public, and GODL’s legal name, remain under consideration and are subject to tax, regulatory and other considerations. Matador’s intention is to monetize its gold tokenization technology through this arrangement, which reflects the Company’s plans as at the date of this news release. The structure ultimately implemented may differ from the arrangement currently contemplated. In any structure, Matador intends that the value created through the monetization of its gold tokenization technology accrue to Matador shareholders. That value may be retained by Matador and reflected in its net asset value, or delivered to shareholders directly, including by way of a dividend or other distribution of securities. The manner and timing of any distribution to shareholders have not been determined and would be subject to the receipt of any required regulatory, Exchange and shareholder approvals. There can be no assurance that any distribution will be made.

GODL is also planning an equity financing and a subsequent public listing on a Canadian stock exchange. The structure, size, pricing and timing of any such financing and listing have not been determined and would remain subject to market conditions, the receipt of regulatory, exchange and shareholder approvals and the satisfaction of other conditions. There can be no assurance that GODL will complete a financing or obtain a listing on the terms contemplated, within the timeframe contemplated, or at all. This news release does not constitute an offer to sell or the solicitation of an offer to buy any securities of GODL.

Hybrid Issuer Status

Matador is classified by the Exchange as a hybrid technology and investment issuer, which permits the Company to make investments in addition to carrying on its technology activities. Under its investment policy, the Company may invest in any industry, with a focus on the Bitcoin, cryptocurrency and precious metals sectors. Potential investments may include digital assets, securities of public and private companies, precious metals, credit products, derivatives, exchange traded funds and other financial instruments, subject to the restrictions in that policy. Bitcoin remains the Company’s primary treasury asset and the principal focus of its capital allocation.

Leadership

Geoff St. Clair, who had served as Vice President, Finance since the Company’s inception, was appointed Chief Financial Officer effective March 26, 2026. Effective July 16, 2026, Donato Sferra, a co-founder and director of the Company, was appointed Chief Executive Officer, and Deven Soni was appointed Executive Chairman.

Outlook

Management believes that Bitcoin has the potential to serve as a long term store of value and reserve asset, and that its role within the global financial system will continue to develop. Matador is intended to provide investors with a publicly listed vehicle through which to obtain exposure to Bitcoin, with that exposure amplified by the Company’s capital structure and supplemented by its yield generation activities. Management intends to pair that exposure with a lean, low cost operating structure, with the objective of building a durable long term business that can maintain its Bitcoin position through periods of price volatility. These are management’s views and are not a prediction of future Bitcoin prices or a guarantee of the Company’s performance. The price of Bitcoin has historically been highly volatile, and an investment in the Company carries risks that differ from, and may be greater than, those of holding Bitcoin directly.

Donato Sferra, Chief Executive Officer of Matador, commented: “Matador’s capital structure reflects a clear view on Bitcoin, and we are open about the fact that it works in both directions. Over the past year we have put the tools in place to add Bitcoin when our cost of capital allows it, and we have brought the cost of running the Company down to a level that matches the business we are today. We are pleased with that progress, and we believe it leaves Matador in a stronger position to pursue future opportunities while remaining disciplined in how we deploy capital.”

Matador intends to remain focused on the priorities described in this news release: holding Bitcoin as its primary treasury asset, using its capital markets tools when management considers doing so accretive to Bitcoin held per share, generating premium income through its yield generation strategy, maintaining a reduced operating cost base, and advancing the licensing of its gold tokenization technology to GODL. Each of these activities remains subject to market conditions and, where applicable, to regulatory, Exchange and shareholder approvals, and there can be no assurance as to the outcome or timing of any of them. The Company expects to provide further updates as developments warrant.

Media Contact:

Donato Sferra
Chief Executive Officer
Email: donato@matador.network
Phone: 647.496.6282

About Matador Technologies Inc.

Matador Technologies Inc. (TSXV:MATA, OTCQB:MATAF, FSE:IU3) is a publicly traded Bitcoin ecosystem company focused on holding Bitcoin as its primary treasury asset and building products to enhance the Bitcoin network. Matador’s strategy combines strategic Bitcoin accumulation, Bitcoin native product development, and digital asset treasury management, with active participation across blockchain and digital assets infrastructure, all with a focus on disciplined capital allocation and cost efficient treasury management.

With a Bitcoin first strategy, and a clear focus on innovation, Matador is shaping the future of financial infrastructure on Bitcoin.

Visit us online at https://www.matador.network/

Cautionary Statement Regarding Forward Looking Information

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This news release does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction.

This news release contains “forward looking information” within the meaning of applicable Canadian securities laws. All statements that are not historical facts are forward looking statements, including, without limitation: (i) statements regarding the effect of the Company’s capital structure on its net asset value; (ii) statements regarding management’s views on Bitcoin and the repayment or conversion of the Notes; (iii) statements regarding the Company’s intended use of the ATM Program, the base shelf prospectus and the Facility, including any follow on closings under the Facility and the application of a portion of the net proceeds of qualifying sales to the purchase of Bitcoin as additional collateral; (iv) statements regarding the proposed Preferred Shares, including shareholder approval, final acceptance by the Exchange and any future issuance; (v) statements regarding the Company’s Bitcoin yield generation strategy and future premium income; (vi) statements regarding the Licence and the transactions contemplated by it, including the final corporate structure by which GODL is established and taken public, GODL’s proposed gold treasury strategy, its intended gold yield strategy, its proposed equity financing and public listing, any cash fee or shares Matador may receive, and any distribution of value to Matador shareholders; (vii) statements regarding the Company’s estimated cash operating expenditures and potential further cost reductions; and (viii) statements regarding potential investments within the digital asset ecosystem.

Forward looking information is based on management’s reasonable assumptions at the time such statements are made, including assumptions regarding market conditions; the price and liquidity of Bitcoin; the Company’s ability to access capital markets on acceptable terms; the Company’s continued compliance with the terms of the Facility; the receipt of all required regulatory and shareholder approvals; the continued availability of the ISDA Agreement with Galaxy; the Company’s ability to sustain its cost reduction measures without disruption to its operations; gold market conditions remaining supportive of GODL’s treasury strategy; and the receipt of the regulatory, exchange and shareholder approvals required for the transactions contemplated by the Licence and for GODL’s proposed financing and listing.

Forward looking statements are subject to various risks and uncertainties, including: fluctuations in the price and trading volume of Bitcoin, the effect of which on the Company’s net asset value is magnified by its use of debt; the risk that the price of Bitcoin does not exceed the Company’s acquisition cost and the costs of maintaining the Facility over the term of the Notes; the Company’s obligations under the Facility, including repayment at maturity and the potential consequences of an event of default; the risk that no additional Notes are issued under the Facility; custody and security risks related to digital assets; the timing and amount of future sales under the ATM Program, if any, and resulting dilution to shareholders; the receipt of shareholder approval and final Exchange acceptance of the Preferred Shares; the performance of covered call and other options strategies and counterparty risk in respect of Galaxy; the execution of the Licence on the terms negotiated, or at all; the determination of the final corporate structure by which GODL is established and taken public; the receipt of approvals for, and the completion of, the transactions contemplated by the Licence; the form and value of any consideration received, including the valuation and liquidity of any shares of GODL held by Matador; the unsecured nature of GODL’s payment obligations to Matador; whether any value from the gold business is ultimately distributed to Matador shareholders, and the manner and timing of any such distribution; GODL’s ability to complete its proposed equity financing and to obtain a public listing on a Canadian stock exchange, or at all; the realization of any net yield on GODL’s gold holdings and its reinvestment in additional gold; volatility in the price of gold; the performance and adoption of tokenized gold products; counterparty and custody risk in respect of physical gold held in LBMA accredited vaults and tokenized gold held with digital asset custodians; the risk that the Company’s actual cash operating expenditures differ from management’s estimate, that further cost reductions are not realized, or that reduced reliance on external advisors affects the Company’s operations; risks associated with any investments the Company may make as a hybrid issuer; evolving regulatory treatment of digital assets; and general market conditions.

Forward looking statements are provided to offer information about management’s current expectations and plans as of the date of this news release and may not be appropriate for other purposes. Readers are cautioned not to place undue reliance on such forward looking information. The Company undertakes no obligation to update or revise any forward looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable securities law.

SOURCE: Matador Technologies Inc.

First Half 2026 and Subsequent Commercial and Operational Highlights

• Completed business combination with NewHold Investment Corp III (“SPAC”) on September 21, 2026 (the “Business Combination”); newcleo’s ordinary shares and warrants commenced trading on the Nasdaq Global Select Market on September 22, 2026 under the symbols “NWCL” and “NWCLW,” respectively
• The Business Combination generated gross proceeds of approximately $247 million, consisting of approximately $31 million released from the SPAC’s trust account and $216 million from the PIPE financing
• Raised approximately $18.7 million in additional financing unrelated to the Business Combination since May 2026, bringing total funds raised since newcleo’s founding to over $1 billion
• Installed the main vessel and turbine for its PRECURSOR non-nuclear 10 MWt demonstration reactor at the ENEA Brasimone Research Center outside Bologna, Italy; completion of construction for PRECURSOR is expected by the end of 2026, with at-scale validation of systems to commence thereafter
• In partnership with Oklo, selected by the U.S. Department of Energy for advanced negotiations under the Surplus Plutonium Utilization Program
• Submitted Regulatory Engagement Plans to the U.S. Nuclear Regulatory Commission for the Company’s LFR-AS-200 lead-cooled fast reactor and its planned U.S. mixed-oxide (MOX) fuel manufacturing facility
• Received notice of an overall opinion of satisfactory compliance from the French Nuclear Safety and Radiation Protection Authority for the proposed safety features for the Company’s planned MOX fuel manufacturing facility in France
• Announced the acquisition, subject to customary closing conditions, of Bonifait Pesage, a French manufacturer of nuclear-grade scales and precision industrial weighing equipment, augmenting the Company’s vertically integrated capabilities
• Announced the appointment of Jeffrey Lyash, a nuclear industry veteran and former head of the Tennessee Valley Authority, as Chairman of the Board of Directors
• Announced the appointment of William D. Magwood as Vice-Chairman of newcleo’s Board of Directors, effective January 1, 2027
• Announced the hiring of Dustin Greenwood as Vice President of U.S. Operations and Travis Chapman as Director of U.S. Regulatory Affairs and Licensing, strengthening the Company’s growing U.S. team
• Announced a partnership with SHINE to assess and jointly pursue opportunities relating to nuclear fuel recycling in the United States and European Union
• On September 10, 2026, newcleo held an Analyst and Investor Day, a recording of which is available on newcleo’s website

First Half 2026 Financial Highlights

• Generated Revenue from Products and Services of approximately €19.4 million, an increase of approximately 46% over First Half 2025
• Reported Net Loss of approximately €82.0 million, an increase of approximately 10% over First Half 2025
• Reported Tangible Capital Expenditures of €25.3 million, an increase of 37% over First Half 2025
• Reported Selling, General & Administrative expenses of €59.2 million, an approximately 21% increase over First Half 2025
• Cash & Cash Equivalents as of June 30, 2026 stood at €66.5 million
• Total ordinary shares outstanding as of the closing date of the Business Combination stood at 281,534,950
• As of September 30, 2026, preliminary, unaudited Cash & Cash Equivalents for the Company stood at approximately €233 million

LONDON, Oct. 02, 2026 (GLOBE NEWSWIRE) — newcleo plc (Nasdaq: NWCL) (“newcleo” or the “Company”), a pioneer in advanced modular reactor (“AMR”) technology and nuclear fuel manufacturing, today announced its operational and financial results for the six months ended June 30, 2026.

“Becoming a public company is a defining milestone for newcleo, and I want to thank every member of our team for the work that brought us to this point and to reporting our first results as a public company,” said Stefano Buono, Founder and CEO of newcleo. “Access to the public markets strengthens our ability to execute on our mission to deliver a credible, near-term path to advanced nuclear deployment and to close the nuclear fuel cycle. The disciplined engineering, licensing, and partnership work carried out by our more than 900 employees across Europe and the United States will continue to drive newcleo’s progress, and I am excited to work with this incredible team every day.

“Importantly, newcleo is moving quickly down the path to both technical validation and regulatory approval for our facilities. The installation of the main vessel for PRECURSOR, our 10 MWt non-nuclear demonstration reactor at Brasimone, is a development milestone for the LFR technology ahead of planned commercial deployment. Completion of construction for PRECURSOR, which is expected by the end of 2026, and beginning the process of reactor system validation, are the next critical steps in qualifying the technology that will lead to the deployment of our LFR-200 reactor.

“In parallel, pre-licensing for our reactor and MOX fuel facilities in France, Slovakia and the United States, including our ongoing engagement with the U.S. Nuclear Regulatory Commission, has moved forward. Our U.S. growth is a particular focus: our work toward siting at Savannah River, and the broader policy support for nuclear expansion in the U.S., position newcleo to play a meaningful role in meeting U.S. energy demand, including from AI infrastructure. We look forward to updating investors on our progress.”

Commercial & Operational Events

On May 26, newcleo was selected by the U.S. Department of Energy for advanced negotiations under the Surplus Plutonium Utilization Program. The program aims to make designated surplus plutonium material available to industry participants and enable the conversion of those materials into fuel for advanced nuclear reactors, subject to U.S. security, safeguards and material accountability requirements. newcleo’s selection, in partnership with Oklo, continues the companies’ strategic partnership as they work together to develop advanced fuel fabrication infrastructure in the U.S.

On June 16, 2026, the Company announced a partnership with SHINE to collaborate on advancing innovative technologies for the recycling of used nuclear fuel. Under the agreement, the parties will assess how SHINE could supply newcleo with reprocessed materials from the used nuclear fuel of traditional reactors to manufacture MOX fuel, and how SHINE could recycle spent fuel from newcleo’s reactors. The parties also intend to jointly pursue U.S. federal funding opportunities and explore additional opportunities for collaboration across both the U.S. and European Union, where spent fuel stockpiles represent a growing strategic priority to support energy independence.

On June 30, 2026, newcleo announced its entry into an agreement to acquire Bonifait Pesage, a French manufacturer of nuclear-grade scales and precision industrial weighing equipment with a strong customer base in the French nuclear ecosystem. Bonifait Pesage manufactures, installs, calibrates, and maintains weighing equipment, while also providing technical support. Since 2017, the company has held key certifications for the maintenance and verification of weighing systems used in ionizing-radiation environments. The acquisition forms part of newcleo’s vertical integration strategy, pursued since 2023, and is expected to close in the fourth quarter of 2026, subject to customary closing conditions. It is intended to bring critical manufacturing capabilities in-house, secure access to nuclear-grade weighing equipment required for planned MOX fuel manufacturing facilities, reduce supply-chain risk and support equipment customization.

Also subsequent to the first half, newcleo progressed work on the PRECURSOR non-nuclear demonstration reactor with the installation of the main vessel and turbine at ENEA’s Brasimone facility located outside of Bologna, Italy. The 10 MWt non-nuclear demonstration reactor, which is scheduled for completion at the end of 2026, is intended to provide the Company with a fully integrated, representative operating and power generating environment for the Company’s planned commercial reactors. Experimental data obtained through the operation of PRECURSOR is expected to inform the Company’s licensing processes on both sides of the Atlantic, including safety computations, system performance analysis and materials development.

“In the first half of 2026, newcleo continued moving our operations forward, continuing to convert planning into reality,” said Elisabeth Rizzotti, Co-Founder, Deputy-CEO and COO of newcleo. “Our OTHELLO test loop is operating, PRECURSOR is under active construction at Brasimone with major components manufactured and installed by our own vertically integrated subsidiaries, which gives us direct control over cost, schedule, and quality across the supply chain rather than relying on third parties for critical systems. At the same time, our work with trusted partners continues to translate into concrete engineering and commercial work. Each of these efforts, testing, building, manufacturing, and partnering, reflects the same discipline: turning our technology roadmap into physical progress on the ground.”

Regulatory Progress

Subsequent to the end of the first half, on July 17, newcleo announced that it had received from the French Nuclear Safety and Radiation Protection Authority (“ASNR”) an overall satisfactory evaluation for the proposed safety features of its planned MOX fuel manufacturing facility in France. The review by the ASNR offers practical feedback to continue developing the facility’s safety features ahead of a license application and valuable experience to support the licensing process in the U.S. The Company is also progressing through a similar regulatory process for its lead-cooled fast reactor design and is currently awaiting the opinion of the ASNR on the proposed safety features of that design.

On August 6, newcleo announced the submission of a Regulatory Engagement Plan (REP) to the U.S. Nuclear Regulatory Commission (NRC) for its planned mixed-oxide (MOX) fuel fabrication facility, to be located in Aiken, South Carolina. The submission of a REP for the MOX facility followed the submission on July 14 to the NRC of a REP for the Company’s LFR-AS-200 reactor. The submitted REPs set out the proposed framework for newcleo’s pre-application engagement with NRC staff in support of the future licensing of both the MOX facility and the LFR-AS-200 lead-cooled fast reactor. The REPs provide an overview of the Company’s proposed licensing approach and an indicative schedule for technical submissions and interactions with the NRC.

Hiring of Key Personnel

On June 11, newcleo announced the hiring of Dustin Greenwood as Vice President of U.S. Operations and Travis Chapman as Director of U.S. Regulatory Affairs and Licensing to direct and support the Company’s growing presence in the U.S. Both Greenwood and Chapman are experienced nuclear professionals, having worked in the U.S. Navy’s nuclear propulsion program, as well as at leading companies developing advanced reactor and nuclear fuel projects. Dustin Greenwood will lead the development of newcleo’s U.S. operational footprint and oversee execution of the Company’s American projects. He will focus on establishing operational capabilities, building strategic partnerships and supporting delivery of the Company’s U.S. deployment roadmap. Travis Chapman will lead newcleo’s U.S. licensing, permitting and regulatory engagement strategy, overseeing the Company’s interactions with federal regulators and supporting the licensing pathway for newcleo’s advanced reactor and fuel technologies.

On September 9, the Company announced the appointment of Jeffrey Lyash to serve as Chairman of the Board of Directors. Lyash brings more than 40 years of experience spanning engineering, procurement, construction, and operations across the power generation, transmission, and distribution sectors. He most recently served as President and Chief Executive Officer of the Tennessee Valley Authority (TVA), the largest public utility in the United States, where he oversaw generation from coal, nuclear, hydroelectric, natural gas, and renewable sources while driving significant improvements in operating efficiency. Prior to TVA, Lyash served as President and CEO of Ontario Power Generation, where he was responsible for $45 billion in assets and an 11,000-person workforce. He also served as President of Chicago Bridge & Iron’s Power Business Unit, leading engineering, procurement, and construction for multi-billion-dollar generation projects globally.

On September 30, the Company announced the appointment of William D. Magwood as Vice-Chairman of newcleo’s Board of Directors, effective January 1, 2027. Magwood has spent the past decade as Director-General of the OECD Nuclear Energy Agency (NEA), where he works directly with the nuclear regulators and energy ministries of NEA’s member countries. Magwood will step down from his position at the NEA at the end of 2026 prior to assuming his position as newcleo’s Vice-Chairman.

First Half Financial Summary

(Amounts in thousands)		For the Six Months Ended
		6/30/2026			6/30/2025
Revenue from Products and Services		€	19,429		€	13,347
Gross Profit			6,130			4,154
Other Income		6,554			4,763
Net Loss		81,981			74,293
Capital Expenditures		26,970			19,000
Cash & Cash Equivalents (end of period)		66,540			131,896

Revenue from Products and Services increased by approximately €6.1 million, or approximately 46%, for the six months ended June 30, 2026, compared to the six months ended June 30, 2025. The increase was attributable to manufacturing and installation of equipment and spare parts for third parties as well as consultancy services.

Other Income increased by approximately €1.8 million, or 38%, for the six months ended June 30, 2026, compared to the six months ended June 30, 2025. The increase was comprised of grant income and an increase in research and development tax credits, both generated in France and Italy, as well as an increase in other income relating to a one-time project outside the Company’s core operations.

Gross Profit increased by approximately €2.0 million, or 48%, for the six months ended June 30, 2026, compared to the six months ended June 30, 2025. The increase in Gross Profit was due to increases in revenue outpacing increases in costs for the First Half 2026.

Net loss increased by approximately €7.7 million, or 10%, for the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to higher non-cash share-based payment expense as well as third-party related expenses.

Tangible capital expenditures were approximately €25.3 million for the six months ended June 30, 2026, compared to approximately €18.5 million for the six months ended June 30, 2025. The increase was due to investments in technology and testing experimental facilities.

Selling, General & Administrative expenses were €59.2 million for the six months ended June 30, 2026, compared to approximately €48.9 million for the six months ended June 30, 2025. The increase in SG&A expense was primarily due to increases in share-based payment expense, and increases in other staff costs related to transaction incentives payable on completion.

The Company had Cash & Cash Equivalents available of €66.5 million as of June 30, 2026, compared to €105.3 million as of December 31, 2025 and €131.9 million as of June 30, 2025.

About newcleo

newcleo is an innovative nuclear technology company developing advanced modular reactors and nuclear fuel designed to deliver clean, safe and sustainable energy at competitive costs. newcleo’s technology combines lead-cooled fast reactors with fuel manufactured from recycled nuclear materials, with the aim of providing abundant and reliable electricity and heat to industrial users while enabling the closure of the nuclear fuel cycle. newcleo brings together more than 900 highly skilled employees across Europe and the United States, spanning reactor and fuel design, engineering, and manufacturing. Through a vertically integrated supply chain and a growing network of strategic partnerships, newcleo is working to turn proven scientific and engineering solutions into deployable nuclear energy assets. For more information visit http://www.newcleo.com

Contacts

For Investors and Media:
newcleo@icrinc.com
media@newcleo.com

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the U.S. federal securities laws. All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding newcleo’s development and commercialization of its lead-cooled fast reactor technology, mixed-oxide fuel capabilities and related products and services; the expected timing, cost, performance and benefits of newcleo’s demonstration projects, fuel facilities, reactor deployments and licensing activities; newcleo’s ability to execute its business strategy, develop its technology, obtain required regulatory approvals, permits and licenses, enter into commercial arrangements, achieve its market opportunity and positioning and support the growth of advanced nuclear energy; newcleo’s expectations regarding strategic partnerships, customer demand, project pipeline, revenue streams, capital expenditures and financing needs; and other statements regarding management’s intentions, beliefs, or expectations with respect to newcleo’s future performance, are forward-looking statements. Forward-looking statements are often identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “develop,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on newcleo’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. You should carefully consider the foregoing factors and the other risks and uncertainties described in other documents filed from time to time by newcleo with the SEC. Additional risks and uncertainties not currently known or that are currently deemed immaterial may also cause actual results to differ materially from those expressed or implied by such forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and newcleo does not assume any obligation or intend to update or revise these forward-looking statements, each of which is made only as of the date of this press release.

Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Income (Unaudited)
	For the six months ended June 30,		For the six months ended June 30 2026
	2026	2025
	(in thousands of euros unless otherwise stated)		Convenience translation into US dollars*
Revenue from Products and Services	19,429	13,347	22,149
Cost of sales	(13,299)	(9,193)	(15,161)
Gross profit	6,130	4,154	6,988
Other income	6,554	4,763	7,472
Research and development expenses	(34,629)	(35,450)	(39,477)
Selling, General and Administrative expenses	(59,170)	(48,932)	(67,454)
Operating loss	(81,115)	(75,465)	(92,471)
Loss on disposal of assets	(9)	(3)	(10)
Finance income	353	1,581	402
Finance costs	(1,448)	(991)	(1,650)
Share of loss of associates	(83)	–	(95)
Loss before income tax	(82,302)	(74,878)	(93,824)
Income tax benefit	321	585	366
Net loss	(81,981)	(74,293)	(93,458)
Other comprehensive income (loss)
Items that may be subsequently reclassified to profit or loss
Currency translation differences	198	(144)	226
Other comprehensive income (loss), net of tax	198	(144)	226
Total comprehensive loss	(81,783)	(74,437)	(93,232)
Net loss attributable to:
Owners of newcleo plc	(81,981)	(74,293)	(93,458)
Non-controlling interest	–	–	–
Total comprehensive loss attributable to:
Owners of newcleo plc	(81,783)	(74,437)	(93,232)
Non-controlling interest	–	–	–
Net loss per share for loss attributable to the ordinary equity holders:
Basic and diluted loss per share	(0.16)	(0.16)	(0.18)

*Convenience translation into US dollars in thousands (exchange rate as at June 30, 2026: EUR 1 = US$ 1.14).

Note: EPS for the period ended June 30, 2026 is calculated based on the number of shares before the share consolidation. Following the closing of the Business Combination, it would be restated to $(0.34). 

Condensed Consolidated Statements of Financial Position (Unaudited)
	June 30, 2026	December 31, 2025	June 30, 2026
	(in thousands of euros unless otherwise stated)		Convenience translation into US dollars*
ASSETS
NON-CURRENT ASSETS
Goodwill	37,281	37,281	42,500
Intangible assets, net	42,760	43,054	48,746
Property, plant and equipment, net	115,999	93,436	132,239
Right-of-use asset	17,665	18,521	20,138
Investments	76	75	87
Investments in associates	31,553	31,635	35,970
Other long-term receivables	34,871	35,207	39,753
Deferred tax assets	3,059	2,176	3,487
TOTAL NON-CURRENT ASSETS	283,264	261,385	322,920
CURRENT ASSETS
Inventories	4,843	5,057	5,521
Short-term investments	2,335	2,291	2,662
Trade receivable, contract and other assets, net	77,768	62,314	88,656
Cash and cash equivalents	66,540	105,270	75,856
TOTAL CURRENT ASSETS	151,486	174,932	172,695
TOTAL ASSETS	434,750	436,317	495,615
NON-CURRENT LIABILITIES
Provisions	4,094	4,170	4,667
Other liabilities	8,932	9,305	10,182
Lease liabilities	14,667	15,537	16,720
Borrowings	15,929	16,306	18,159
Deferred tax liabilities	4,430	4,244	5,050
TOTAL NON-CURRENT LIABILITIES	48,052	49,562	54,778
CURRENT LIABILITIES
Provisions	378	186	431
Trade and other payables	60,055	83,808	68,463
Lease liabilities	3,545	3,250	4,041
Borrowings	2,497	2,583	2,847
TOTAL CURRENT LIABILITIES	66,475	89,827	75,782
TOTAL LIABILITIES	114,527	139,389	130,560
EQUITY
Share capital	5,046	4,739	5,752
Share premium	23,378	562,904	26,652
Other reserves	57,067	51,383	65,057
Retained earnings (accumulated deficits)	234,695	(324,123)	267,552
Equity attributable to owners of newcleo plc	320,186	294,903	365,013
Non-controlling interests	37	2,025	42
TOTAL EQUITY	320,223	296,928	365,055
TOTAL EQUITY AND LIABILITIES	434,750	436,317	495,615

*Convenience translation into US dollars in thousands (exchange rate as at June 30, 2026: EUR 1 = US$ 1.14).

Condensed Consolidated Cash Flow Statement (Unaudited)
	For the six months ended June 30		For the six months ended June 30 2026
	2026	2025
	(in thousands of euros)		Convenience translation into US$*
Cash flows from operating activities
Net loss	(81,981)	(74,293)	(93,458)
Adjustments to reconcile net loss to net cash flows:
Loss from associates	83	–	95
Finance income	(30)	(1,476)	(34)
Finance costs	1,131	830	1,289
Income tax benefit	(321)	(585)	(366)
Depreciation of property, plant and equipment and right-of-use assets, amortization intangible assets and provisions	8,286	7,397	9,446
Share-based payment expense	21,010	4,975	23,951
Loss on disposals	9	4	10
Other revenues and expenses without effect on cash flow	3	5	3
Changes in working capital:			–
Decrease in inventory	214	94	244
(Increase) in trade receivables, contract and other assets	(15,217)	(6,781)	(17,347)
Increase (decrease) in trade and other payables	13,077	(2,428)	14,908
Income taxes received	49	25	56
Net cash flows used in operating activities	(53,687)	(72,233)	(61,203)
Cash flows from investing activities
Acquisition of intangible assets	(1,642)	(458)	(1,872)
Purchase of property, plant and equipment	(25,328)	(18,542)	(28,874)
Proceeds from maturities of short-term investments	–	997	–
Purchase of short-term investments	(41)	(160)	(47)
Interest received from short-term investments	30	1,477	34
Decrease (increase) in loans and deposits made	4	(2)	5
Proceeds from sale of tangible and intangible assets	10	5	12
Net cash flows used in investing activities	(26,967)	(16,683)	(30,742)
Cash flows from financing activities
Proceeds from issues of shares	45,121	–	51,438
Proceeds from issue of shares to non-controlling shareholders	–	31,637	–
Repayments of borrowings and lease liabilities	(2,129)	(2,535)	(2,427)
Interest expenses including interest on lease	(1,131)	(800)	(1,289)
Net cash flows from financing activities	41,861	28,302	47,722
Net decrease in cash and cash equivalents	(38,793)	(60,614)	(44,223)
Cash and cash equivalents at the beginning of the period	105,270	192,714	120,008
Effect of foreign exchange rate changes	63	(204)	71
Cash and cash equivalents at the end of the period	66,540	131,896	75,856

*Convenience translation into US$ in thousands (exchange rate as at June 30, 2026: EUR 1 = US$ 1.14)

Stockholm, 1st of October 2026 – Virtune today announces the completion of the monthly rebalancing for the Virtune Crypto Top 10 Index ETP, listed on Nasdaq Stockholm for both the SEK-denominated (ISIN code SE0020052207, ticker name VIR10SEK) and the EUR-denominated (ISIN code SE0020052215, ticker name VIR10EUR) ETP.

In addition to the Virtune Crypto Top 10 Index ETP, Virtune’s product portfolio includes:

Virtune Arbitrum ETP
Virtune Avalanche ETP
Virtune Bitcoin ETP
Virtune Bitcoin Prime ETP
Virtune Bittensor ETP
Virtune BNB ETP
Virtune Chainlink ETP
Virtune Coinbase 50 Index ETP
Virtune Crypto Altcoin Index ETP
Virtune Hyperliquid ETP
Virtune Litecoin ETP
Virtune Polygon ETP
Virtune Stablecoin Index ETP
Virtune Staked Cardano ETP
Virtune Staked Ethereum ETP
Virtune Staked NEAR ETP
Virtune Staked Polkadot ETP
Virtune Staked Solana ETP
Virtune Stellar ETP
Virtune Sui ETP
Virtune XRP ETP

Index allocation as of 30th of September (before rebalancing):

Bitcoin: 38.85%
Ethereum: 30.78%
BNB: 9.55%
XRP: 9.12%
Solana: 6.60%
Hyperliquid: 1.83%
Chainlink: 1.06%
Cardano: 0.86%
Stellar: 0.75%
Bitcoin Cash: 0.59%

Index allocation as of 30th of September (after rebalancing):

Bitcoin: 40.00%
Ethereum: 30.56%
BNB: 9.71%
XRP: 8.59%
Solana: 6.36%
Hyperliquid: 1.92%
Chainlink: 0.89%
Cardano: 0.82%
Stellar: 0.67%
Bitcoin Cash: 0.49%

In connection to this month’s rebalancing, there are no changes to the crypto assets included in the index.

The performance of the Virtune Crypto Top 10 Index ETP SEK for September was +9.34%.

The rebalancing is carried out according to the index that the ETP tracks, the Virtune Crypto Top 10 Index. The purpose of the monthly rebalancing is to ensure that the ETP always reflects the current market conditions and to effectively absorb volatility in the crypto market.

Virtune’s crypto index ETP is the first of its kind in the Nordic region. The ETP includes up to 10 leading crypto assets and are based on their total market capitalization, with a maximum weight of 40% per crypto asset to promote diversification. This allows investors to benefit from broad exposure to the crypto market without being heavily concentrated in any single crypto asset.

If you, as an (institutional) investor, are interested in meeting with Virtune to discuss the opportunities our ETPs offer for your asset management services or to learn more about Virtune and our ETPs, please do not hesitate to contact us at hello@virtune.com. You can also read more about Virtune and our ETPs at www.virtune.com and register your email address on our website to subscribe to our newsletters, which cover updates on Virtune’s upcoming ETP launches and other news related to digital assets.

Press contact
Christopher Kock, CEO Virtune AB (Publ)
Christopher@virtune.com
+46 70 073 45 64

Virtune with its headquarters in Stockholm is a regulated Swedish digital asset manager and issuer of crypto exchange traded products on regulated European exchanges. With regulatory compliance, strategic collaborations with industry leaders and our proficient team, we empower investors on a global level to access innovative and sophisticated investment products that are aligned with the evolving landscape of the global crypto market.

Cryptocurrency investments are associated with high risk. Virtune does not provide investment advice. Investments are made at your own risk. Securities may increase or decrease in value, and there is no guarantee that you will recover your invested capital. Please read the prospectus, KID, terms at www.virtune.com.

BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that there will be multiple presentations at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, from October 22 to 25. The final efficacy analysis of the ORIGIN 3 trial of TRUTAKNA in IgA nephropathy (IgAN) will be a featured late-breaking oral presentation during the opening plenary session and also a late-breaking research poster. In addition, interim results from the adult IgAN and primary membranous nephropathy (pMN) cohorts in PIONEER, a Phase 2 basket trial of atacicept in multiple glomerular diseases, will be a late-breaking research oral presentation. In total, five Vera sponsored abstracts will be presented at ASN Kidney Week 2026, demonstrating the Company’s commitment to transforming medicine in autoimmune kidney disease.

Vera Therapeutics Abstract Presentations at ASN Kidney Week 2026
Oral Presentations
Title	The ORIGIN 3 Trial of Atacicept in IgA Nephropathy
Presenting Author	Jonathan Barratt, PhD, FRCP, Mayer Professor of Renal Medicine, University of Leicester
Abstract Number	TH-OR109
Session Title	Opening Plenary
Session Date, Time	Thursday, October 22, 8:00–9:30 AM MDT
Presentation Time	9:05–9:12 AM MDT
Location	Bluebird Ballroom, Convention Center
Supplementary Poster Session	Late-Breaking Research Posters, Thursday, October 22
Poster Board	TH-PO1257
Title	Interim Results from the Adult IgAN and Primary Membranous Nephropathy (pMN) Cohorts in the Atacicept PIONEER Trial
Presenting Author	Richard Lafayette, MD, FACP, Professor of Medicine (Nephrology) and Director of the Glomerular Disease Center at Stanford University Medical Center
Abstract Number	SA-OR079
Session Title	Late-Breaking Research Orals: Pediatrics, Genetics, and Glomerular Diseases
Session Date, Time	Saturday, October 24, 4:30–6:00 PM MDT
Presentation Time	5:30–5:40 PM MDT
Location	Four Seasons Ballroom 2, Convention Center
Poster Presentations
Title	The PIONEER Trial: Expanding Evaluation of Atacicept, a B-Cell-Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL) Inhibitor, to Pediatric Patients with IgAN
Presenting Author	Howard Trachtman, MD, University of Michigan
Session Date, Time	Saturday, October 24, 10:00 AM–12:00 PM MDT
Location	Exhibit Hall, Convention Center
Poster Board	INFO20-SA
Title	Rapid Progression in IgAN Despite Treatment: Real-World Evidence of Suboptimal Disease Control in the United States
Presenting Author	Damemarie Paul, DrPH, MPH, Vera Therapeutics
Session	Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research – Other [PO1402-07]
Session Date, Time	Saturday, October 24, 10:00 AM–12:00 PM MDT
Location	Exhibit Hall, Convention Center
Poster Board	SA-PO0627
Title	Aurora: A Multi-Site Clinical Implementation Network for IgA Nephropathy
Presenting Author	Navdeep Tangri, MD, University of Manitoba
Session Date, Time	Saturday, October 24, 10:00 AM–12:00 PM MDT
Location	Exhibit Hall, Convention Center
Poster Board	INFO19-SA

TRUTAKNA (atacicept-vymj) Indication

TRUTAKNA (atacicept-vymj) is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression.

This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether TRUTAKNA slows kidney function decline over the long-term in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.

Important Safety Information

Contraindications: TRUTAKNA is contraindicated in patients with serious hypersensitivity to atacicept-vymj or any excipients of TRUTAKNA.

Warnings and Precautions

Immunosuppression and Increased Risk of Infections: TRUTAKNA suppresses the immune system by reducing antibody production, which may increase the risk of infections. Patients with chronic infection or recurring infections may have an increased risk of serious infection. In clinical trials, infections were reported in 32% of TRUTAKNA patients compared with 28% of placebo patients.

Before initiating TRUTAKNA, assess patients for active infections. Delay TRUTAKNA administration in patients with active infection until the infection resolves or is adequately treated. Monitor patients for signs and symptoms of infection during treatment with TRUTAKNA. If a serious infection develops, consider interrupting TRUTAKNA until the infection is controlled.

The concomitant use of TRUTAKNA and other immune-modulating therapies has not been evaluated. Concomitant use of TRUTAKNA with drugs that affect the immune system, including systemic corticosteroids, may increase the risk of infection.

Immunosuppression and Immunization Risk: TRUTAKNA may interfere with the immune response to vaccines and increase the risk of infection from live vaccines. Prior to initiating treatment with TRUTAKNA, complete all age-appropriate immunizations. Live vaccines are not recommended within 30 days prior to initiation or during treatment with TRUTAKNA as safety of coadministration has not been established.

Adverse Reactions: The most common adverse reactions (≥5%) in patients treated with TRUTAKNA and placebo, respectively, were infections (32% vs 28%) and local administration reactions (30% vs 5%). The most common infection was upper respiratory tract infection (12% vs 9%), and the most common local administration reactions were injection site reaction (19% vs 2%) and injection site erythema (6% vs 1%).

Use in Specific Populations

Pregnancy: Available data on TRUTAKNA used in pregnant women exposed during clinical trials are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.

Based on the mechanism of action, TRUTAKNA may cause immunosuppression in the in utero-exposed infant. Consider the potential clinical impact of TRUTAKNA exposure in infants exposed in utero. Pregnant women exposed to TRUTAKNA, or their healthcare provider, should report TRUTAKNA exposure by calling 1-833-633-8372.

Pediatric Use: The safety and effectiveness of TRUTAKNA in pediatric patients have not been established.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Vera Therapeutics at 1-833-MED-VERA or medinfo@veratx.com.

Please see full Prescribing Information for additional Important Safety Information.

About TRUTAKNA

TRUTAKNA, a B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) inhibitor, is a soluble recombinant fusion protein containing the human transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) receptor that binds to the cytokines BAFF and APRIL.¹ BAFF and APRIL are key cytokines that activate B cells and drive IgAN pathophysiology. In IgAN, activated B cells produce both the antigen and associated antibodies that result in the production of damaging IgA immune complexes. The overlapping roles of BAFF and APRIL in activating B cells support the potential for TRUTAKNA as a disease-modifying therapy.² TRUTAKNA is self-administered as an at-home, small-volume (1 ml), 150 mg once-weekly autoinjector.

TRUTAKNA TRU SUPPORT™ Patient Support Program

We are dedicated to ensuring that eligible IgAN patients can access the first approved therapy that targets both BAFF and APRIL. TRUTAKNA TRU SUPPORT, our patient support program, offers insurance coverage assistance, financial assistance options for eligible patients, and educational resources designed to support patient access and care. Eligible commercially insured patients may pay as little as $0 out of pocket through our copay assistance program. More information will be available on www.veratx.com.

About IgAN

IgAN is a serious, progressive, immune-mediated kidney disease and a leading cause of chronic kidney disease and kidney failure worldwide.^3,4 Approximately 2.5 adults per 100,000 worldwide are diagnosed with IgAN each year, most often between 30 and 40 years of age.^5,6 Over time, IgAN can lead to irreversible kidney damage and may ultimately require dialysis or kidney transplantation. At least 50% of patients may progress to kidney failure or death within 10 to 20 years of diagnosis.³

About Vera Therapeutics

Vera Therapeutics is a commercial-stage biotechnology company focused on the pursuit of truth in science to transform medicine in autoimmune disease, starting with the kidney. Vera Therapeutics’ flagship commercial product is TRUTAKNA (atacicept-vymj), a BAFF and APRIL inhibitor indicated to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies through inhibition of BAFF and APRIL may prove clinically meaningful. Vera Therapeutics was founded in 2016 and is based in Brisbane, California. To learn more, visit www.veratx.com.

Forward-looking Statements

Statements contained in this press release regarding matters, events or results that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the potential for TRUTAKNA as a disease-modifying therapy; Vera Therapeutics’ commitment to transforming medicine in autoimmune kidney disease; and the plans, commitments, aspirations and goals under the caption “About Vera Therapeutics”. Words such as “anticipate,” “believe,” “expect,” “may,” “plan,” “potential,” “will” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Vera Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks related to the regulatory approval process, risks related to commercial launch, market acceptance, and payer coverage, results of earlier clinical trials may not be obtained in later clinical trials, preliminary results may not be predictive of topline results, risks and uncertainties associated with Vera Therapeutics’ business in general, the impact of macroeconomic and geopolitical events, and the other risks described in Vera Therapeutics’ filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Vera Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

References

1. TRUTAKNA™ [Prescribing Information]. Brisbane, CA: Vera Therapeutics, Inc; July 2026

2. Cheung CK, Barratt J, Liew A, Zhang H, Tesar V, Lafayette R. The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies. Front Nephrol. 2024;3:1346769. Published 2024 Feb 1. doi:10.3389/fneph.2023.1346769

3. Pitcher D, Braddon F, Hendry B, et al. Long-Term Outcomes in IgA Nephropathy. Clin J Am Soc Nephrol. 2023;18(6):727-738. doi:10.2215/CJN.0000000000000135

4. McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011;26(2):414-430. doi:10.1093/ndt/gfq665

5. Jarrick S, Lundberg S, Welander A, et al. Mortality in IgA Nephropathy: A Nationwide Population-Based Cohort Study. J Am Soc Nephrol. 2019;30(5):866-876. doi:10.1681/ASN.2018101017

For more information, please contact:
Investor Contact:
Joshua Qin
Vera Therapeutics
650-360-6978
ir@veratx.com

Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com

YANTAI, China, Oct. 02, 2026 (GLOBE NEWSWIRE) — Decent Holding Inc. (NASDAQ: DXST) (the “Company”), a technology-driven provider of wastewater treatment and community-based senior health and elderly care services in China today announced that it has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with an institutional investor for the sale of (i) in a registered direct offering, 822,828 Class A ordinary shares, par value of $0.0025 per share, of the Company (the “Class A Ordinary Shares”) or, in lieu thereof, pre-funded warrants, at a purchase price of $1.50 per share; and (ii) in a concurrent private placement, unregistered warrants (the “Unregistered Warrants”) to purchase up to 822,828 Class A Ordinary Shares, with an exercise price of $1.50 per share (together, the “Securities”).

The gross proceeds from the offering of the Class A Ordinary Shares (or pre-funded warrants in lieu thereof) are expected to be approximately $1.23 million, before deducting placement agent fees and other offering expenses.

The offering is expected to close on or about October 5, 2026, subject to the satisfaction of customary closing conditions.

The Company expects to use the net proceeds from this offering for working capital and general corporate purposes.

FT Global Capital, Inc. is acting as the exclusive placement agent for the offering.

The offering of the Class A Ordinary Shares (or pre-funded warrants in lieu thereof) is being made pursuant to the Company’s “shelf” registration statement on Form F-3 (File No. 333-295313), which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 24, 2026, and declared effective on May 7, 2026. A prospectus supplement and the accompanying prospectus relating to the Class A Ordinary Shares (or pre-funded warrants in lieu thereof) will be filed with the SEC and will be available on the SEC’s website at www.sec.gov.

The Unregistered Warrants were issued in a concurrent private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Regulation D promulgated thereunder and, along with the Class A ordinary shares underlying the warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the warrants and underlying Class A ordinary shares may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Decent Holding Inc.

Decent Holding Inc. (NASDAQ: DXST) specializes in the provision of wastewater treatment by cleansing industrial wastewater, ecological river restoration and river ecosystem management by enhancing water quality, as well as microbial products primarily used for pollutant removal and water quality enhancement, through the Company’s operating subsidiary, Shandong Dingxin Ecology Environmental Co., Ltd. In addition, through its operating subsidiary Suncare (Shanghai) Health Technology Co., Ltd., the Company operates an AI-powered, community-based senior health and elderly care platform serving China’s aging population. For more information, please visit the Company’s website.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “plan,” “should,” “could,” “believe,” “expect,” “anticipate,” “project,” “estimate,” “potential”, or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances, except as required by applicable law.

Investor Relations Contact:

WFS Investor Relations Inc.
Connie Kang, Partner
Email: ckang@wfsir.com
Tel: +86 1381 185 7742

• Oral presentation highlighting updated clinical data from at least 20 patients with refractory rheumatoid arthritis (RA), 11 patients with Sjögren disease (SjD) and at least five patients with systemic sclerosis (SSc) treated with AlloNK plus rituximab in the ongoing Phase 2a basket trial, all with at least six months of follow-up
• Poster presentation highlighting deep, consistent B-cell depletion comparable to that observed with CD19 CAR T-cell therapies and a favorable tolerability profile across immune-mediated diseases
• Poster presentation characterizing the high unmet medical need and low clinical response rates among patients with refractory RA following an inadequate response to at least two distinct classes of biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), a population similar to that being studied in the Phase 3 registrational trial
• Live webcast on Monday, November 9, 2026 at 8:15 am EST to review Artiva’s presentations, including an in-depth analysis of data from at least 10 patients with refractory RA who have at least six months of follow-up and would meet key eligibility criteria for the Phase 3 registrational trial

SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) — Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced one oral and two poster presentations at ACR Convergence 2026 featuring updated data from its AlloNK^® program and a registry analysis of the high unmet medical need in refractory RA.

Artiva will host a live webcast on Monday, November 9, 2026, at 8:15 am EST to review its ACR presentations and updated clinical data from at least 20 patients with refractory RA who have at least six months of follow-up. The webcast will include an in-depth analysis of data from at least 10 of these patients who would meet key eligibility criteria for the Phase 3 registrational trial.

The following abstracts will be presented at ACR Convergence 2026, taking place November 6 – 11, 2026, at the Orange County Convention Center in Orlando:

1899 Oral Presentation	AB-101, Outpatient-Administered, Non-Genetically Modified NK Cells in Combination with Rituximab Generate Robust Efficacy Responses Comparable with Autologous CAR T in 34 Patients with Rheumatologic Diseases
Presenting Author:	Guillermo J. Valenzuela, M.D., F.A.C.R. Medical Director, Integral Rheumatology & Immunology Specialists
Session:	Abstracts: Rheumatoid Arthritis – Treatment
Date/Time/Location:	Monday, November 9, 2026 at 3:00 – 4:30 pm EST
2384 Poster	AB-101, Outpatient-Administered, Non-Genetically Modified NK Cells in Combination with Rituximab, Demonstrates Favorable Safety Profile in a Large Cohort of 60 Patients with Rheumatological Diseases while Consistently Achieving Deep B-cell Depletion
Presenting Author:	Subhashis Banerjee, M.D. Chief Medical Officer, Artiva Biotherapeutics
Session:	Poster Session C: Rheumatoid Arthritis – Treatment
Date/Time/Location:	Tuesday, November 10, 2026 at 10:30 am – 12:30 pm EST, WB1 & 2
2402 Poster	High Unmet Need and Low Clinical Response Rates Among Rheumatoid Arthritis Patients Failing Two or More Classes of b/tsDMARDs: A United States Registry Analysis
Presenting Author:	Jonathan Kay, M.D., M.A.C.R. Timothy S. and Elaine L. Peterson Chair in Rheumatology, UMass Chan Medical School
Session:	Poster Session C: Rheumatoid Arthritis – Treatment
Date/Time/Location:	Tuesday, November 10, 2026 at 10:30 am – 12:30 pm EST, WB1 & 2

For more information on these and other abstracts, please visit the ACR Convergence 2026 website.

Virtual Webcast Details
Investors and the general public are invited to register for the webcast here. A live question-and-answer session will follow the presentation. A replay will be available for 90 days in the Investors section of Artiva’s website.

About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases. Artiva is initiating a Phase 3 registrational trial of its lead program, AlloNK^® (also known as AB-101), for refractory rheumatoid arthritis (RA) during the second half of 2026. AlloNK is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved natural killer (NK) cell therapy candidate designed to enhance antibody-dependent cellular cytotoxicity in combination with a range of therapeutic antibodies. Initial clinical data evaluating AlloNK in combination with anti-CD20 antibodies have demonstrated encouraging activity across multiple B-cell-driven autoimmune diseases and a tolerability profile supportive of outpatient administration. Artiva is developing AlloNK plus rituximab as a scalable, outpatient-administered, deep B-cell depletion treatment regimen for use in community rheumatology settings. In addition to refractory RA, AlloNK is being evaluated in Sjögren disease, systemic sclerosis and myositis.

Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: the potential benefits, accessibility, practicality, effectiveness, safety and tolerability of AlloNK, including based on interim pooled data across clinical trials, and the potential for administration in an outpatient community setting; the registrational Phase 3 trial for AlloNK, including trial design, expectations for response rates, and timing of initiation, future updates on site activation and enrollment, and topline data readout; and Artiva’s ability to generate sufficient data to support a BLA submission; clinical data expected to be presented from patients with refractory RA, SjD and SSc, and the timing of such data disclosures; the number of patients with data from the basket study who would be expected to meet the key eligibility criteria for the planned Phase 3 trial; Artiva’s ability to realize the potential benefits associated with FDA RMAT designation for AlloNK; Artiva’s beliefs regarding its competitive position, including its belief that AlloNK may be the first deep B-cell depleting therapy of any modality to reach patients with, and be approved and commercialized in, refractory RA; and Artiva’s future results of operations and financial position, including cash runway. These forward-looking statements are based on the beliefs of the management of Artiva as well as assumptions made by and information currently available to Artiva. Such statements reflect the current views of Artiva with respect to future events and are subject to known and unknown risks and uncertainties, including, without limitation, risks and delays relating to initiation of the Phase 3 registrational trial, activation of clinical trial sites, patient enrollment and the availability and timing of disclosure of data; risks that future clinical trial results may not be consistent with interim, initial, preliminary, or topline results or results from prior preclinical studies or clinical trials, or with Artiva’s expectations; the risk that the number of patients, or the duration of follow-up for such patients, available for presentation differs from current expectations; the risk that differences exist between trial designs, patient characteristics and other factors for the Phase 3 trial, Artiva-sponsored Phase 2a basket trial and investigator-initiated basket trial, and caution should be exercised in drawing any conclusions from such data across separate trials as such pooling and comparative data is inherently limited and such data may not be directly comparable; the risk that other deep B-cell depleting therapies may advance more rapidly than Artiva currently anticipates, that Artiva’s assessment of publicly disclosed competitor development timelines may be incomplete or inaccurate, and that Artiva may not achieve or be the first to achieve regulatory approval or commercialization of a therapy in this category; the risk that Artiva’s registrational strategy is based in part on recent interactions with the FDA and later feedback from the FDA may be inconsistent with past interactions; Artiva’s ability to obtain adequate financing to fund its planned clinical trials and other expenses; risks inherent in developing product candidates; and risks related to the legal and regulatory framework for the industry. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause Artiva’s actual results to differ from current expectations are discussed in Artiva’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in Artiva’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, Artiva undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Investors & Media
Noopur Batsha Liffick, MPH
NBL LifeSci Advisory LLC
ir@artivabio.com

Source: Artiva Biotherapeutics, Inc.

AB “Ignitis grupė” (hereinafter – the Group) announces that Kepler Cheuvreux, a leading independent European financial services company, with a strong presence in equity research and brokerage, has initiated sponsored research of the Group’s stock and published the initiation report.

Its research includes insights on the Group’s performance, potential, estimates and valuation. The initiation report and subsequent updates will be publicly available on Kepler Cheuvreux Research Hub here.

“We welcome Kepler Cheuvreux’s initiation of equity research coverage of Ignitis Group. As Europe’s leading independent equity broker, Kepler Cheuvreux brings an additional independent perspective on our performance, strategy and long-term value creation. Its analysis will further strengthen our visibility and engagement across the capital markets,” says Jonas Rimavičius, CFO and member of the Management Board of Ignitis Group.

The recommendations and consensus of equity research analysts covering the Group’s stock is available here.

Legal notice:
The research is prepared by Kepler Cheuvreux under a sponsored research arrangement and reflects the independent views of its authors. The reports are prepared based on publicly available information, provided for information purposes only and does not constitute investment advice or a recommendation to buy, sell or hold securities. The Group assumes no responsibility for the analyses, opinions or conclusions contained in the report. Any investment decision remains solely the responsibility of the investor.

For additional information, please contact:

Communications
Valdas Lopeta
+370 621 77993
valdas.lopeta@ignitis.lt 

Investor Relations
Ainė Riffel-Grinkevičienė
+370 643 14925
aine.riffel-grinkeviciene@ignitis.lt

• New immune data from the phase 2 trial with EVX-01 to be presented both in an oral and poster presentation
• New data follows from the three-year clinical update for EVX-01 to be provided at the European Society for Medical Oncology (ESMO) 2026 congress on October 24, 2026

COPENHAGEN, Denmark, October 2, 2026 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, will present new immune data for AI-designed personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place in Phoenix, Arizona, November 4-8, 2026.

The new data will reflect the systemic immunomodulatory effects of EVX-01 plus pembrolizumab beyond vaccine-specific T-cell responses using comprehensive immune profiling. It will be presented both in an oral and poster presentation at the SITC meeting.

The new immune data stems from the phase 2 trial investigating EVX-01 in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with advanced melanoma. Each patient enrolled in the trial received a unique vaccine designed and manufactured based on their individual biology. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

The complete three-year clinical data from the phase 2 trial will be presented at the European Society for Medical Oncology (ESMO) 2026 congress on October 24, 2026. Two-year data demonstrated an Objective Response Rate (ORR) of 75% as 12 out of 16 patients had objective clinical responses, with four patients obtaining a complete response. Additionally, a durable clinical benefit was observed as 92% of patients were still responding at two years follow-up and no relapses were observed.

In the third year, patients received EVX-01 as stand-alone therapy, meaning the data will offer insight into the vaccine’s effect also when not administered in combination with anti-PD-1 therapy. Further, the data may also provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune response.

SITC oral and poster presentation details:

• Abstract title: EVX-01 personalized AI-designed vaccine plus pembrolizumab induce neoantigen-specific T-cell responses and systemic immune modulation in advanced melanoma
• Abstract#: 502

Oral presentation:

• Session: 105b: Rapid Oral – Clinical 1
• Location: Phoenix Convention Center, West Building-300 Level – 301BC
• Date/Time: Friday, November 6, 2026, 12:30-1:30pm MT / 20:30-21:30 CET       
• Presenter: Mads Lausen, Senior Scientist at Evaxion

Poster presentation:

• Session: Poster Session
• Location: Phoenix Convention Center, North Building-Lower Level – Exhibition Halls 4-6
• Date/Time: Saturday, November 7, 2026, 12:30-1:30pm & 6:40-8:10pm MT / 20:30-21:30 CET & 02:40-04:10 CET (Sunday, November 8)
• Presenter: Mads Lausen, Senior Scientist at Evaxion

About EVX-01
EVX-01 is a personalized peptide-based cancer vaccine intended for first-line treatment of multiple advanced solid cancer tumors. It is currently being evaluated as a treatment of advanced melanoma and is Evaxion’s lead clinical asset.

Designed with our AI-Immunology™ platform, EVX-01 is tailored to target the unique tumor profile and immune characteristics of each patient. It engages the patient’s immune system to fight off cancer by mounting a targeted response against tumor-specific neoantigens.

In the phase 2 trial in patients with advanced melanoma (skin cancer), EVX-01 has demonstrated an Objective Response Rate (ORR) of 75% as 12 out of 16 patients had objective clinical responses, with four patients obtaining a complete response. 86% of the EVX-01 neoantigen targets triggered a tumor-specific immune response in the patients.

Contact information 
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai

About Evaxion
Evaxion is a pioneering clinical-stage TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer as well as infectious and autoimmune diseases.

With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development.

We have developed a pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.

For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website. 

Forward-looking statement 
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.